Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN‐812 (Viloxazine Extended‐Release) Pharmacokinetics in Healthy Adults

SPN‐812 (viloxazine extended‐release) is a novel nonstimulant recently approved as a treatment for attention‐deficit/hyperactivity disorder in children and adolescents. Given that SPN‐812 is metabolized by CYP2D6 and may be coadministered with CYP2D6 inhibitors, this trial investigated the pharmacok...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhao, Kosheleff, Alisa R., Adeojo, Lilian W., Odebo, Oyinkansola, Adewole, Toyin, Qin, Peibing, Maletic, Vladimir, Schwabe, Stefan, Nasser, Azmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597116/
https://www.ncbi.nlm.nih.gov/pubmed/33943033
http://dx.doi.org/10.1002/cpdd.948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597116/
https://www.ncbi.nlm.nih.gov/pubmed/33943033
http://dx.doi.org/10.1002/cpdd.948

Ejemplares similares